Dalgety, a medical cannabis producer based in Leicestershire, has recently announced a new contract agreement with Grow Pharma and its licensed partner JV Partner IPS Pharma. This partnership will enable the commercial supply of pharmaceutical-grade THC-rich prescription medicines to the UK market ¹². The CEO of Grow Pharma, Pierre van Weperen, said that this collaboration is a positive step towards bringing UK-grown medicines with industry-leading expertise to the pharmaceutical market ¹.

If you’re interested in reading more about cannabis, you can check out Cannabis Health News for the latest news, legislative updates, and industry insights.

Learn more:

1. thebusinessdesk.com2. cannabishealthnews.co.uk3. dalgetyuk.co.uk

Dalgety is a UK-based producer of high-quality pharmaceutical cannabis for distribution to the medical industry. The company was founded in 2016 and is dedicated to the research and development of the highest-grade product, with consistent levels of cannabinoids for prescription medicines. Dalgety’s state-of-the-art facility combines human-led techniques with AI-controlled management for the best growing and processing practices ¹.

Following the UK government’s decision to permit the use of prescription medical cannabis in 2018, Dalgety is ideally positioned as a UK producer for distribution directly to the medical market ¹.

Cannabis has been used as a natural remedy by diverse cultures for over 10,000 years. Scientific study is ongoing into the multiple uses and conditions that cannabinoids can relieve. Only recently has it been possible to identify and extract the individual active ingredients for research to identify any benefits for a wide range of medical conditions ¹.

Dalgety aims to produce consistently high-quality ingredients through environmentally controlled hydroponic growing and pharmaceutical grade manufacturing processes and be recognized as the leading supplier to the medical community ¹.

Learn more:

1. dalgetyuk.co.uk2. dalgetyuk.co.uk3. thecannabispages.com4. cannabishealthnews.co.uk5. thebusinessdesk.com

What is hydroponic growing?

Hydroponic growing is a method of growing plants without soil. Instead, plants are grown in a nutrient-rich water solution ¹. The roots of the plants are suspended in the solution, which is carefully balanced to provide the necessary nutrients for growth ¹. Hydroponic growing can be done indoors or outdoors and is often used to grow crops such as lettuce, tomatoes, and herbs ¹. There are two basic types of hydroponic systems: those requiring aggregates or other porous rooting media to support the plant roots and those not needing aggregates to support the plant roots ¹. The most widely used term for the latter type is nutrient film technique (NFT) ¹. Hydroponic growing has several advantages over traditional soil-based growing, including faster growth rates, higher yields, and more efficient use of resources such as water and fertilizer ².

Learn more:

1. rhs.org.uk2. foodrevolution.org3. weedmaps.com

Dalgety, a leading medical cannabis producer based in the Midlands, United Kingdom, has made a significant announcement that marks a notable development in the field of medical cannabis supply in the country. The reputable company has entered into a strategic contract agreement with Grow Pharma, a well-established cannabis pharmaceutical firm, and its licensed joint venture (JV) partner, IPS Pharma. This remarkable collaboration is poised to revolutionize the accessibility and availability of pharmaceutical-grade, THC-rich prescription medicines within the UK market. Dalgety’s decision to partner with Grow Pharma and IPS Pharma, two recognized names in the field of pharmaceutical cannabis, adds a promising new dimension to their business model. This alliance aims to foster the commercial supply of a specialized category of medicines containing a rich concentration of Tetrahydrocannabinol (THC), a crucial compound found in cannabis. The medicinal properties of THC are increasingly recognized by the medical fraternity, and this venture is set to cater to the growing demand for such prescription drugs. The agreement stands to enable Dalgety, renowned for its commitment to superior quality and assurance in its products, to extend its reach in the pharmaceutical industry. This partnership allows them to tap into the expertise and extensive network of Grow Pharma and IPS Pharma, thereby consolidating its presence in the commercial supply of THC-rich prescription medicines. It’s a significant leap forward in Dalgety’s mission to improve consumer access to reliable, pharmaceutical-grade cannabis. Grow Pharma, on the other hand, stands to benefit from this agreement as well. By entering into a contract with Dalgety, they can expand their product portfolio with a trusted partner, renowned for its high-quality medical cannabis production. This agreement means that Grow Pharma, along with its licensed JV partner, IPS Pharma, will be able to extend their product range to include THC-rich prescription medicines, thereby further enhancing their reputation and appeal in the market. The collaboration between these three entities also signifies a significant development for the wider UK market. The availability of pharmaceutical-grade, THC-rich prescription medicines has been a need for some time now, and with this agreement, it seems the UK market is set to be well catered for. This new contract agreement between Dalgety, Grow Pharma, and IPS Pharma is not merely a business transaction. It is an endeavor to broaden patient access to high-quality, THC-rich medicines, and a commitment to exploiting the therapeutic potential of cannabis for the welfare of the UK population. It mirrors a leap forward in the medical cannabis industry, likely to set the tone for future collaborations and breakthroughs.

In the first month of this year, a landmark event occurred in the rapidly evolving field of medical cannabis. Dalgety, a noted player in the sector, was officially granted a license by the Home Office. This critical legal endorsement didn’t just come from any organization; it was issued by the UK Home Office, a department of the government of the United Kingdom responsible for immigration, security, and law and order. The significance of this cannot be understated. The UK Home Office is a highly respected institution, and their granting of this license to Dalgety only underscores the legitimacy and importance of the company’s work. The license was not for a vague or generic purpose. It specifically permits Dalgety to cultivate and manufacture medical cannabis. But not just any type of medical cannabis. The license explicitly mentions EU-GMP grade medical cannabis, a classification that speaks volumes about the quality and potency of the product. EU-GMP, or European Union Good Manufacturing Practice, is a system for ensuring that products are consistently produced and controlled according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product. The high standards of EU-GMP grade products make them the preferred choice for medical purposes, ensuring that patients get the very best that the industry has to offer. The specific type of medical cannabis that Dalgety has been permitted to manufacture is high-THC cannabis. Tetrahydrocannabinol or THC is one of the many compounds found in cannabis, and it is primarily responsible for the plant’s psychological effects. The high-THC tag indicates that the cannabis plants to be cultivated by Dalgety will have a particularly high concentration of this compound, making them potentially more effective in treating certain medical conditions. The granting of this license to Dalgety is not just a commercial milestone for the company itself, but also a significant development for the entire medical cannabis industry. It marks a growing recognition of the potential benefits of cannabis and its compounds in the medical field, and opens up exciting new possibilities for research and treatment. Furthermore, the license also means that Dalgety’s facility will become a key hub in the cultivation and production of high THC-medical cannabis. The organization’s infrastructure, research capabilities, and manufacturing prowess will play a crucial role in shaping the landscape of medical cannabis in the future. This development, therefore, represents not just a triumph for Dalgety, but a significant step forward for the entire industry.

After years of anticipation and intense research and development, the company is now on the brink of launching its ground-breaking first product. The much-anticipated debut is scheduled for the end of 2023, a milestone that is anticipated with great eagerness not just by the company’s staff and stakeholders, but also by countless medical practitioners and patients across the UK. This product, heralding a new era in the medical field, will be the first-ever UK-grown cannabis-based medicine available for prescription. This is a significant accomplishment that is expected to reshape healthcare in the country, and potentially, around the world. The introduction of this product will be a groundbreaking feat in the UK’s medical history. Not only is it the first of its kind to be grown and developed within UK borders, but it also represents the culmination of years of scientific research and experimentation, pushing the boundaries of medicine and pharmacology. This pioneering product is the result of the tireless efforts of the company’s dedicated team of scientists, researchers, and medical experts who have been working relentlessly to develop a safe, effective, and reliable cannabis-based medication. However, it’s not just about the scientific achievement. It’s also about the potential benefits for millions of patients who could be aided by this medication. The company’s pioneering cannabis-based medicine is expected to provide tangible health benefits that could significantly improve the quality of life for patients suffering from a variety of conditions. Conditions that have been, until now, inadequately managed with existing treatments. The fact that this is a UK-grown product also has significant implications. It fosters a sense of pride and accomplishment within the country, as it reflects the ability of UK scientists and researchers to be at the cutting edge of medical advancements. Furthermore, being a domestically produced product means less dependency on imports, thus aiding the local economy and potentially creating jobs within the country. The timing of the launch, set for the end of 2023, also gives the company sufficient time to ensure all necessary quality checks and regulations are meticulously adhered to. It also allows time for medical practitioners to familiarize themselves with the new treatment option, and prepare for its integration into their practice. This unprecedented development marks a new chapter in UK’s medical history and is expected to pave the way for further innovation in the field of cannabis-based medicine. The ripple effects of this product release are sure to be felt far beyond the shores of the UK, potentially inspiring similar advancements in other countries. In conclusion, the end of 2023 is set to be a monumental time for the UK’s medical landscape. This momentous occasion marks the arrival of the first UK-grown cannabis-based medicine on the market, a product that is anticipated to be a game-changer for patients and healthcare practitioners alike.

James Leavesley, chief operating officer at Dalgety, said: “We began discussions with Grow more than two years ago and we share its ambition as a leader within the medical cannabis industry. From cultivation and processing, through to patient experience, we’re aligned in our aim of providing the highest quality medicine and service to patients. I’m excited to announce that this agreement has now come to fruition.” 

The United Kingdom’s (UK) medical cannabis market is projected to undergo a substantial growth, with estimates forecasting that it will reach a value exceeding £1 billion by 2026. This development is significant in terms of the potential boost it could offer the UK’s economic growth, creating a new profitable industry within the nation. The medical cannabis industry in the UK is still in its nascent stages, with the full potential of its market yet to be realized. However, the forecast for its growth is highly promising. It is anticipated that the market value will exceed the billion-pound mark within the next five years. This prediction indicates a considerable upsurge, keeping in mind that the industry is still relatively new in the territory. The growth of the medical cannabis market is expected to have a positive impact on the UK’s economy. The burgeoning industry is poised to contribute significantly to the country’s economic growth. The increase in market value implies a surge in trade, which could lead to higher revenues for the government from taxes and duties. It could also result in job creation in the sector, with a range of roles from cultivation to distribution to research, thus reducing unemployment rates and contributing to the overall welfare of the citizens. The potential for growth in this sector is impressive and industry leaders are urging the government to harness this opportunity for the betterment of the UK’s economy. The escalating global acceptance and legalization of medical cannabis could play a pivotal role in encouraging investment in the sector, potentially attracting international stakeholders to invest in the UK’s burgeoning market. In conclusion, the anticipated growth in the UK’s medical cannabis market could have a profound impact on its economy. A market value exceeding £1 billion by 2026 would not only signify the industry’s potential but also its contribution to the nation’s economic growth. As the UK and the world at large continue to navigate the landscape of medical cannabis, this forecast represents a glimpse into a future of significant financial growth and economic stability. The expansion of the medical cannabis market in the UK is not just about a rise in financial figures. It represents a shift in attitudes towards medical cannabis usage, increased acceptance of its therapeutic benefits, and a willingness to invest in research and development for further advancements. The economic benefits are an added advantage that could help boost the country’s overall growth in the coming years. As the industry evolves, it will be fascinating to watch the trends and developments that unfold in the UK’s medical cannabis market.